Navigation Links
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Date:1/20/2011

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg. The NDA is based on the reference listed drug Combivir®, by ViiV Healthcare. This innovative pediatric fixed-dose combination (FDC) in tablet form was developed by Matrix for use in treating children with HIV/AIDS. This product will be eligible for purchase outside the U.S. in certain developing countries.

Mylan President Heather Bresch said: "The approval of Lamivudine and Zidovudine is particularly important because it makes available an innovative FDC treatment option for children who are living with HIV/AIDS in developing countries. The addition of this product to our ARV franchise is a critical next step in helping to extend and improve the quality of life of people living with HIV/AIDS and to continue to expand access to high quality, affordable ARVs."

Lamivudine and Zidovudine Tablets, a combination of two nucleoside analogue reverse transcriptase inhibitors, are used in combination with other medications to control HIV infection. The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards.

Matrix's wide range of ARV products includes active pharmaceutical ingredients and 34 first- and second-line finished doses, eight of which are pediatric products. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per patient of effective therapies. Approximately 30% of HIV/AIDS patients in developing countries depend on a Matrix ARV product.

Mylan Inc. rank
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Matrixx Initiatives, Inc. and H.I.G. Capital Announce Early Termination of HSR Waiting Period
2. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
3. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
4. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
6. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results
7. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
8. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
9. DynaMatrix™ to be Featured on Discovery Channel Segment Highlighting Innovative Products in Oral Health
10. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results
11. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)... Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... treatments for cancer and its associated pain, today announced ... development of a small molecule inhibitor targeting the important ... protein has also been recognized as an important determinant ... as a dominant factor in most human cancers and ...
(Date:7/21/2014)... MARYVILLE, Ill. , July 21, 2014 /PRNewswire-iReach/ ... that Dr. Ryan Diederich has been ... on Membership and Advocacy for 2014-2015. This council ... member resources, services and benefits. The ... that represents and unifies its physician members as ...
Breaking Medicine Technology:Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4
... Dec. 21, 2011  VIVUS, Inc. (NASDAQ: VVUS ... retrospective study of medical claims data on oral ... utero .  The study, known as FORTRESS for ... mother-infant dyads exposed to topiramate either alone (monotherapy) ...
... Dec. 21, 2011 Despite the numerous medical advances ... the United States is still higher than most European ... the growing rate of pre-term births, researchers are committed ... Northwestern Medicine ® researchers are examining ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6Northwestern Researchers Trial New Device that May Support Improved Newborn Health 2Northwestern Researchers Trial New Device that May Support Improved Newborn Health 3Northwestern Researchers Trial New Device that May Support Improved Newborn Health 4
(Date:7/22/2014)... 2014 A new and technologically unique ... with results that are surprising even the most skeptical ... skin with radio frequency, ThermiTight has been dubbed “InjectableRF” ... the skin to “inject” heat to the tissues which ... single treatment solution for skin laxity produces results in ...
(Date:7/21/2014)... On Monday, September 22, 2014 Push to Walk will ... Solutions at The Knoll West Country Club, Knoll & Greenbank ... at 11 a.m. The price of $225 includes all ... $250 after September 7th. Non-golfers and guests are welcome ... dinner will include a special silent and live auction in ...
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
(Date:7/21/2014)... Center for Public Affairs Research has released the results ... what it means to be a quality health care ... the Robert Wood Johnson Foundation, sheds new light on ... care and doctors, as well as the information they ... survey produces new and actionable data during a crucial ...
Breaking Medicine News(10 mins):Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... of therapeutic agents that interferes with the ability of ... The results of the new study will be presented ... Meeting in San Francisco. , The cell-based study ... compounds are likely to be effective against breast cancers ...
... scientists work collaboratively, barriers of religion and ethnicity ... science to improve the lives of citizens worldwide. ... Gluck, professor of neuroscience at Rutgers University in ... after successfully organizing an international conference co-hosted by ...
... 16 Pittsburgh-based Foundation,Radiology Group (FRG) and Cherry ... which will make FRG the exclusive provider of,diagnostic ... Kishor E. Joshi, M.D., president of Cherry Tree ... Foundation Radiology Group. We expect,this partnership will enhance ...
... Association, a,regional non-profit established to foster relationships and ... announced today,the election of five new officers and ... New officers who were elected to serve a ... president, Aon Consulting; Past President - Thomas,Hoffman, partner, ...
... studies indicate that oral use of RU-486,s companion drug misoprostol ... , The off-label use of a drug given with RU-486 ... of rare, fatal infections seen in women taking the drugs ... , The drug misoprostol is FDA-approved to be taken ...
... & Lymphoma Society,s Light The Night(R) Walk Offers Relief at ... the ... prices may be,putting the brakes on Americans, summer travel plans, but The ... cards,and a chance to win an all-expense paid vacation., Light The ...
Cached Medicine News:Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:US-Israeli-Palestinian collaboration to advance Alzheimer's disease research 2Health News:Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services 2Health News:SouthWest Benefits Association Elects New Board of Directors 2Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3Health News:Get Free Gas and Help Save a Life 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: